Clinical significance of the measurements of urinary liver-type fatty acid binding protein levels in patients with acute coronary syndrome

Journal of Cardiology

Volumn 60, Issue 3, 2012, Pages 168-173

  Matsumori, Rie ^a   Shimada, Kazunori ^a   Kiyanagi, Takashi ^a   Hiki, Makoto ^a   Fukao, Kosuke ^a   Hirose, Kuniaki ^a   Ohsaka, Hiromichi ^a   Miyazaki, Tetsuro ^a   Kume, Atsumi ^a   Yamada, Atsushi ^a   Takagi, Atsutoshi ^a   Ohmura, Hirotoshi ^a   Miyauchi, Katsumi ^a   Daida, Hiroyuki ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Acute coronary syndrome; Cardio renal interaction; Cardiovascular events; Urinary albumin; Urinary liver type fatty acid binding protein

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; BRAIN NATRIURETIC PEPTIDE; CLOPIDOGREL; FATTY ACID BINDING PROTEIN; HEPARIN; UNCLASSIFIED DRUG; URINARY ALBUMIN; URINARY LIVER TYPE FATTY ACID BINDING PROTEIN;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ADULT; AGED; ANGIOCARDIOGRAPHY; ANTICOAGULANT THERAPY; ARTICLE; CEREBROVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; LENGTH OF STAY; LOADING DRUG DOSE; MALE; PERCUTANEOUS CORONARY INTERVENTION; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; RESTENOSIS; UNSTABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; BIOLOGICAL MARKERS; CATHETER ABLATION; FATTY ACID-BINDING PROTEINS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS;

EID: 84866146230     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2012.03.008     Document Type: Article

References (31)

1. Bagshaw S.M., Cruz D.N., Aspromonte N., Daliento L., Ronco F., Sheinfeld G., Anker S.D., Anand I., Bellomo R., Berl T., Bobek I., Davenport A., Haapio M., Hillege H., House A., et al. Epidemiology of cardio-renal syndromes: workgroup statements from the 7th ADQI consensus conference. Nephrol Dial Transplant 2010, 25:1406-1416.
2. Ix J.H., Shlipak M.G., Liu H.H., Schiller N.B., Whooley M.A. Association between renal insufficiency and inducible ischemia in patients with coronary artery disease: the heart and soul study. J Am Soc Nephrol 2003, 14:3233-3238.
3. Sarnak M.J., Levey A.S., Schoolwerth A.C., Coresh J., Culleton B., Hamm L.L., McCullough P.A., Kasiske B.L., Kelepouris E., Klag M.J., Parfrey P., Pfeffer M., Raij L., Spinosa D.J., Wilson P.W., et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003, 108:2154-2169.
4. Shiba N., Shimokawa H. Chronic kidney disease and heart failure - bidirectional close link and common therapeutic goal. J Cardiol 2011, 57:8-17.
5. Matsuo K., Inoue T., Node K. Estimated glomerular filtration rate as a predictor of secondary outcomes in Japanese patients with coronary artery disease. J Cardiol 2009, 53:232-239.
6. Cruz D.N., Bagshaw S.M. Heart-kidney interaction: epidemiology of cardiorenal syndromes. Int J Nephrol 2010, 2011:351291.
7. Yamamoto T., Yamamoto A., Watanabe M., Matsuo T., Yamazaki N., Kataoka M., Terada H., Shinohara Y. Classification of FABP isoforms and tissues based on quantitative evaluation of transcript levels of these isoforms in various rat tissues. Biotechnol Lett 2009, 31:1695-1701.
8. Maatman R.G., van de Westerlo E.M., van Kuppevelt T.H., Veerkamp J.H. Molecular identification of the liver- and the heart-type fatty acid-binding proteins in human and rat kidney. Use of the reverse transcriptase polymerase chain reaction. Biochem J 1992, 288:285-290.
9. Kamijo A., Sugaya T., Hikawa A., Okada M., Okumura F., Yamanouchi M., Honda A., Okabe M., Fujino T., Hirata Y., Omata M., Kaneko R., Fujii H., Fukamizu A., Kimura K. Urinary excretion of fatty acid-binding protein reflects stress overload on the proximal tubules. Am J Pathol 2004, 165:1243-1255.
10. Star R., Hostetter T., Hortin G.L. New markers for kidney disease. Clin Chem 2002, 48:1375-1376.
11. Kamijo A., Kimura K., Sugaya T., Yamanouchi M., Hikawa A., Hirano N., Hirata Y., Goto A., Omata M. Urinary fatty acid-binding protein as a new clinical marker of the progression of chronic renal disease. J Lab Clin Med 2004, 143:23-30.
12. McMahon B.A., Murray P.T. Urinary liver fatty acid-binding protein: another novel biomarker of acute kidney injury. Kidney Int 2010, 77:657-659.
13. Fukuda Y., Miura S., Zhang B., Iwata A., Kawamura A., Nishikawa H., Shirai K., Saku K. Significance of urinary liver-fatty acid-binding protein in cardiac catheterization in patients with coronary artery disease. Inter Med 2009, 48:1731-1737.
14. Hiki M., Shimada K., Ohmura H., Kiyanagi T., Kume A., Sumiyoshi K., Fukao K., Inoue N., Mokuno H., Miyazaki T., Daida H. Serum levels of remnant lipoprotein cholesterol and oxidized low-density lipoprotein in patients with coronary artery disease. J Cardiol 2009, 53:108-116.
15. Matsuo S., Imai E., Horio M., Yasuda Y., Tomita K., Nitta K., Yamagata K., Tomino Y., Yokoyama H., Hishida A. Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009, 53:982-992.
16. Okazaki S., Yokoyama T., Miyauchi K., Shimada K., Kurata T., Sato H., Daida H. Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study. Circulation 2004, 110:1061-1068.
17. Masaki Y., Shimada K., Kojima T., Miyauchi K., Inoue K., Kiyanagi T., Hiki M., Fukao K., Hirose K., Ohsaka H., Kume A., Miyazaki T., Ohmura H., Ohsaka A., Daida H. Clinical significance of the measurements of plasma N-terminal pro-B-type natriuretic peptide levels in patients with coronary artery disease who have undergone elective drug-eluting stent implantation. J Cardiol 2011, 57:303-310.
18. Miyazaki T., Shimada K., Miyauchi K., Kume A., Tanimoto K., Kiyanagi T., Sumiyoshi K., Hiki M., Mokuno H., Okazaki S., Sato H., Kurata T., Daida H. Effects of fenofibrate on lipid profiles, cholesterol ester transfer activity, and in-stent intimal hyperplasia in patients after elective coronary stenting. Lipids Health Dis 2010, 9:122.
19. Harjai K.J., Raizada A., Shenoy C., Sattur S., Orshaw P., Yaeger K., Boura J., Aboufares A., Sporn D., Stapleton D. A comparison of contemporary definitions of contrast nephropathy in patients undergoing percutaneous coronary intervention and a proposal for a novel nephropathy grading system. Am J Cardiol 2008, 101:812-819.
20. Kamijo-Ikemori A., Sugaya T., Yasuda T., Kawata T., Ota A., Tatsunami S., Kaise R., Ishimitsu T., Tanaka Y., Kimura K. Clinical significance of urinary liver-type fatty acid-binding protein in diabetic nephropathy of type 2 diabetic patients. Diabetes Care 2011, 34:691-696.
21. Veerkamp J.H., Peeters R.A., Maatman R.G. Structural and functional features of different types of cytoplasmic fatty acid-binding proteins. Biochim Biophys Acta 1991, 1081:1-24.
22. Sasaki H., Kamijo-Ikemori A., Sugaya T., Yamashita K., Yokoyama T., Koike J., Sato T., Yasuda T., Kimura K. Urinary fatty acids and liver-type fatty acid binding protein in diabetic nephropathy. Nephron Clin Pract 2009, 112:148-156.
23. Oliver M.F., Opie L.H. Effects of glucose and fatty acids on myocardial ischemia and arrhythmias. Lancet 1994, 343:155-158.
24. Matthys E., Patel Y., Kreisberg J., Stewart J.H., Venkatachalam M. Lipid alterations induced by renal ischemia: pathogenic factor in membrane damage. Kidney Int 1984, 26:153-161.
25. Cantor W.J., Kim H.H., Jolly S., Moe G., Burstein J.M., Mendelsohn A., Kleinfeld A.M., Fitchett D. B-type natriuretic peptide and serum unbound free fatty acid levels after contemporary percutaneous coronary intervention. J Invasive Cardiol 2008, 20:186-188.
26. Guarda E., Godoy I., Foncea R., Pérez D.D., Romero C., Venegas R., Leighton F. Red wine reduces oxidative stress in patients with acute coronary syndrome. Int J Cardiol 2005, 104:35-38.
27. Yamamoto T., Noiri E., Ono Y., Doi K., Negishi K., Kamijo A., Kimura K., Fujita T., Kinukawa T., Taniguchi H., Nakamura K., Goto M., Shinozaki N., Ohshima S., Sugaya T. Renal L-type fatty acid-binding protein in acute ischemic injury. J Am Soc Nephrol 2007, 18:2894-2902.
28. Noiri E., Doi K., Negishi K., Tanaka T., Hamasaki Y., Fujita T., Portilla D., Sugaya T. Urinary fatty acid-binding protein 1: an early predictive biomarker of kidney injury. Am J Physiol Renal Physiol 2009, 296:669-679.
29. Nakamura T., Inoue T., Sugaya T., Kawagoe Y., Suzuki T., Ueda Y., Koide H., Node K. Beneficial effects of olmesartan and temocapril on urinary liver-type fatty acid-binding protein levels in normotensive patients with immunoglobin A nephropathy. Am J Hypertens 2007, 20:1195-1201.
30. Nakamura T., Sugaya T., Kawagoe Y., Ueda Y., Osada S., Koide H. Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy. Diabetes Care 2005, 28:2728-2732.
31. Nakamura T., Sugaya T., Kawagoe Y., Ueda Y., Koide H. Effect of pioglitazone on urinary liver-type fatty acid-binding protein concentrations in diabetes patients with microalbuminuria. Diabetes Metab Res Rev 2006, 22:385-389.